Table 1. New targeted drugs.
| Target | Drug | Phase of studies |
|---|---|---|
| pan RAF | TAK-632 | Preclinical |
| ARQ736 | I | |
| ERK1/2 | MK-8353 | I |
| BVD-523 | I | |
| AEZS-131 | Preclinical | |
| SCH772984 | Preclinical | |
| CDK4/6 | Dinaciclib (MK-7965) | II |
| P276-00 | II | |
| LEE011 | Ib/II | |
| Palbociclib (PD-0332991)* | I, III (breast cancer) | |
| PanPI3K | Buparlisib (BKM120) | I, III (breast cancer) |
| Pictilisib (GDC-0941) | I | |
| PX-866 | I | |
| PI3K specific isoforms | BAY-80-6946 | I |
| BYL-719 | I | |
| PI3K/MTOR | BGT-226 | I |
| BEZ-235 | I (clinical development stopped) | |
| GSK-2126458 | I | |
| AKT | MK-2206 | I |
| MET | ARQ-197 | I |
| MET, VEGFR2 | E7050 | II |
| Ac anti MET | Onartuzumab | I |
| IGFR1 | Ganitumumab (AMG479) | I |
| panFGFR | SU5402 | Preclinical |
| BGJ398 | I | |
| HSP90 | Ganetespib (STA-9090) | II |
| XL888 | I | |
| VEGFR1, 2, 3, PDGFR, CKIT | Pazopanib* | II |
| VEGFR2, MET, AXL, RET,KIT, FLT3 | Cabozantinib* | I, II |
| BRAFV600, BRAF, CRAF, VEGFR2, PDGFR, CRAF, CSF, RET, ckit, SRC | RAF-265 | II |
| NOTCH1 | RO-4929097 | II (clinical development stopped) |
| PF-03084014 | I | |
| TGF-β | Trabedersen (AP12009) | I-II |
| Tasisulam (LY573636) | III (prematurely closed due to toxicity) | |
| EW7203 | Preclinical | |
| Galunisertib (LY2157299) | Preclinical | |
| STAT/JAK3 | WP1066 | I |
| YAP-TEAD | Verteporfin | II |
*, FDA approval in other tumors.